Quotient currently operates from three sites in Edinburgh, UK and offices in Switzerland and the US.
Where we’ve come from
The history of Quotient begins with the Scottish National Blood Transfusion Service (SNBTS), which has manufactured blood typing reagents since the early 1940’s.
- • 1990
- Diagnostics manufacture was centralised in Edinburgh with formation of the National Reagents Unit (NRU)
- • 1998
- SNBTS created ‘Diagnostics Scotland’ by merging the NRU and the Scottish Antibody Production Unit (SAPU)
- • 2005
- Diagnostics Scotland rebranded as ‘Alba Bioscience’
- • 2007
- Privatisation of Alba Bioscience – acquired by Quotient Bioscience Group
- • 2008
- Quotient Biodiagnostics Inc established in US
- • 2011
- Control transferred to Quotient Biodiagnostics Group
- • 2013
- Alba Bioscience rebranded as ‘Quotient’
- • 2014
- Quotient Suisse SA established in Eysins. Flotation on US Stock Market (NASDAQ)
The majority of our products are used in the field of Immunohaematology and are used to ensure, as far as possible, the safe transfusion of blood and blood products. To this end our products are subjected to very high quality standards as the result of any error in blood typing could have very serious implications for the patient.
Our products and services include those used:
- To determine the blood group of blood donations and patients
- To work as a control in order to validate test results and equipment
- For the detection and identification of unexpected antibodies in blood
- For the assessment of staff competence in the transfusion laboratory
We also produce niche products used for more in-depth testing, for example in complex cases where samples require further investigation to identify irregular blood groups or blood group antibodies.
Transforming Transfusion Diagnostics
The immediate future focus for Quotient is the development of our presence in the US marketplace. Since 2009, Quotient has built a direct commercial infrastructure in North America and the United Kingdom, while we continue to serve the OEM market. Quotient has over 200 products it manufactures and sells worldwide in over 30 countries.
The next phase for Quotient is its development project, MosaiQ™. This is an automated, multiplexed diagnostic platform for donor and patient blood testing utilizing a protein microarray based on long established serologic reactions.
The goal is to create a single assay capable of incorporating antigen typing, antibody identification and viral screening. The MosaiQ™ project would consolidate what in today’s environment would require a number of automated platforms and manual testing into a single platform and single assay.